{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:26:02Z","timestamp":1779236762886,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1124\/mol.116.105346","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T01:58:39Z","timestamp":1467856719000},"page":"188-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers"],"prefix":"10.1016","volume":"90","author":[{"given":"Chunlong","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiantao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/mol.116.105346_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra0707279","article-title":"Update on avian influenza A (H5N1) virus infection in humans","volume":"358","author":"Abdel-Ghafar","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/mol.116.105346_bib2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/17460441.2012.674510","article-title":"Screening methods for influenza antiviral drug discovery","volume":"7","author":"Atkins","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/mol.116.105346_bib3","doi-asserted-by":"crossref","first-page":"11872","DOI":"10.1021\/bi9014488","article-title":"Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus","volume":"48","author":"Balannik","year":"2009","journal-title":"Biochemistry"},{"key":"10.1124\/mol.116.105346_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.antiviral.2010.09.020","article-title":"Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model","volume":"88","author":"Bantia","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.antiviral.2013.07.018","article-title":"New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions","volume":"100","author":"Beyleveld","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrmicro3380","article-title":"Molecular mechanisms of antibiotic resistance","volume":"13","author":"Blair","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1124\/mol.116.105346_bib7","first-page":"44","article-title":"High levels of adamantane resistance among influenza A (H3N2)viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season","volume":"55","author":"Bright","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1124\/mol.116.105346_bib8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nature08722","article-title":"Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers","volume":"463","author":"Cady","year":"2010","journal-title":"Nature"},{"key":"10.1124\/mol.116.105346_bib9","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1021\/ja102581n","article-title":"Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy","volume":"133","author":"Cady","year":"2011","journal-title":"J Am Chem Soc"},{"key":"10.1124\/mol.116.105346_bib10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3201\/eid1506.081357","article-title":"Oseltamivir- and amantadine-resistant influenza viruses A (H1N1)","volume":"15","author":"Cheng","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1124\/mol.116.105346_bib11","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","article-title":"HIV drug resistance","volume":"350","author":"Clavel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1124\/mol.116.105346_bib12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd2424","article-title":"The design of drugs for HIV and HCV","volume":"6","author":"De Clercq","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/mol.116.105346_bib13","article-title":"Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/mol.116.105346_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S1473-3099(14)70821-7","article-title":"Antiviral combinations for severe influenza","volume":"14","author":"Dunning","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1124\/mol.116.105346_bib15","unstructured":"Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NSCenters for Disease Control and Prevention (CDC)Advisory Committee on Immunization Practices (ACIP) (2008) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 57 (RR-7):1\u201360."},{"key":"10.1124\/mol.116.105346_bib16","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1093\/jac\/dkt251","article-title":"Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B","volume":"68","author":"Fofana","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/mol.116.105346_bib17","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1128\/AAC.48.12.4855-4863.2004","article-title":"Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells","volume":"48","author":"Govorkova","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/mol.116.105346_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.280.1.35","article-title":"Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up","volume":"280","author":"Gulick","year":"1998","journal-title":"JAMA"},{"key":"10.1124\/mol.116.105346_bib19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1124\/mol.116.105346_bib20","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1128\/JCM.43.8.4139-4146.2005","article-title":"Enhanced expression of an \u03b12,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor","volume":"43","author":"Hatakeyama","year":"2005","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"10.1124\/mol.116.105346_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/irv.12045","article-title":"Newer influenza antivirals, biotherapeutics and combinations","volume":"7","author":"Hayden","year":"2013","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1124\/mol.116.105346_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/infdis\/jiq012","article-title":"Emerging influenza antiviral resistance threats","volume":"203","author":"Hayden","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1124\/mol.116.105346_bib23","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/pro.2158","article-title":"Structural basis for proton conduction and inhibition by the influenza M2 protein","volume":"21","author":"Hong","year":"2012","journal-title":"Protein Sci"},{"key":"10.1124\/mol.116.105346_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coviro.2014.04.009","article-title":"The epidemiology and spread of drug resistant human influenza viruses","volume":"8","author":"Hurt","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1124\/mol.116.105346_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.antiviral.2009.03.003","article-title":"Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa","volume":"83","author":"Hurt","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2006.01.012","article-title":"Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants","volume":"70","author":"Ilyushina","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/135965350701200302","article-title":"Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice","volume":"12","author":"Ilyushina","year":"2007","journal-title":"Antivir Ther"},{"issue":"Suppl 3","key":"10.1124\/mol.116.105346_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/irv.12170","article-title":"Influenza prevention and treatment in transplant recipients and immunocompromised hosts","volume":"7","author":"Ison","year":"2013","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1124\/mol.116.105346_bib29","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1073\/pnas.0804958105","article-title":"Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel","volume":"105","author":"Jing","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.116.105346_bib30","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(08)61125-3","article-title":"Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series","volume":"372","author":"Kandun","year":"2008","journal-title":"Lancet"},{"key":"10.1124\/mol.116.105346_bib31","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/nm.2954","article-title":"The ongoing battle against influenza: Drug-resistant influenza viruses: why fitness matters","volume":"18","author":"Kelso","year":"2012","journal-title":"Nat Med"},{"key":"10.1124\/mol.116.105346_bib32","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1073\/pnas.0811720106","article-title":"Molecular dynamics calculations suggest a conduction mechanism for the M2 proton channel from influenza A virus","volume":"106","author":"Khurana","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.116.105346_bib33","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/acs.jmedchem.5b01910","article-title":"Discovery of highly potent inhibitors targeting the predominant drug-resistant S31N mutant of the influenza A virus M2 proton channel","volume":"59","author":"Li","year":"2016","journal-title":"J Med Chem"},{"key":"10.1124\/mol.116.105346_bib34","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1128\/JVI.77.15.8418-8425.2003","article-title":"Overexpression of the \u03b1-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors","volume":"77","author":"Matrosovich","year":"2003","journal-title":"J Virol"},{"issue":"Suppl 1","key":"10.1124\/mol.116.105346_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm-Breschkin","year":"2013","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1124\/mol.116.105346_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/9781118636817.ch2","article-title":"Influenza pandemics: history and lessons learned","author":"Monto","year":"2013","journal-title":"Textbook of Influenza"},{"key":"10.1124\/mol.116.105346_bib37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0092-8674(92)90452-I","article-title":"Influenza virus M2 protein has ion channel activity","volume":"69","author":"Pinto","year":"1992","journal-title":"Cell"},{"key":"10.1124\/mol.116.105346_bib38","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1074\/jbc.R500020200","article-title":"The M2 proton channels of influenza A and B viruses","volume":"281","author":"Pinto","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.116.105346_bib39","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.37.3.540","article-title":"Strategic design and three-dimensional analysis of antiviral drug combinations","volume":"37","author":"Prichard","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/mol.116.105346_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"Prichard","year":"1990","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib41","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1126\/science.1221466","article-title":"Influenza: options to improve pandemic preparation","volume":"336","author":"Rappuoli","year":"2012","journal-title":"Science"},{"key":"10.1124\/mol.116.105346_bib42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/JVI.01067-13","article-title":"Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro","volume":"88","author":"Renzette","year":"2014","journal-title":"J Virol"},{"key":"10.1124\/mol.116.105346_bib43","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1124\/mol.116.105346_bib44","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2013.03.014","article-title":"Influenza virus resistance to neuraminidase inhibitors","volume":"98","author":"Samson","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib45","doi-asserted-by":"crossref","first-page":"A46","DOI":"10.1016\/j.antiviral.2007.01.055","article-title":"Anti-influenza A synergistic combination effect of rimantadine and oseltamivir in mice","volume":"74","author":"Simeonova","year":"2007","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2008.01.023","article-title":"In vivo synergistic combination effect of rimantadine and oseltamivir against influenza A(H3N2) is manifested in several dose ratios","volume":"78","author":"Simeonova","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.antiviral.2012.05.004","article-title":"Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice","volume":"95","author":"Simeonova","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib48","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/AAC.01012-08","article-title":"Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice","volume":"53","author":"Smee","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/mol.116.105346_bib49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2010.07.003","article-title":"Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice","volume":"88","author":"Smee","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2012.03.001","article-title":"Combinations of favipiravir and peramivir for the treatment of pandemic influenza A\/California\/04\/2009 (H1N1) virus infections in mice","volume":"94","author":"Tarbet","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1124\/mol.116.105346_bib51","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.292.11.1333","article-title":"Influenza-associated hospitalizations in the United States","volume":"292","author":"Thompson","year":"2004","journal-title":"JAMA"},{"key":"10.1124\/mol.116.105346_bib52","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1124\/mol.116.105346_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jac\/dkq387","article-title":"Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181","volume":"66","author":"Triana-Baltzer","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/mol.116.105346_bib54","doi-asserted-by":"crossref","first-page":"12773","DOI":"10.1128\/JVI.79.20.12773-12782.2005","article-title":"TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments","volume":"79","author":"Vingerhoets","year":"2005","journal-title":"J Virol"},{"key":"10.1124\/mol.116.105346_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ja.2013.49","article-title":"Prospects for new antibiotics: a molecule-centered perspective","volume":"67","author":"Walsh","year":"2014","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1124\/mol.116.105346_bib56","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1128\/jvi.67.9.5585-5594.1993","article-title":"Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block","volume":"67","author":"Wang","year":"1993","journal-title":"J Virol"},{"key":"10.1124\/mol.116.105346_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/fvl.15.95","article-title":"M2 as a target to combat influenza drug resistance: what does the evidence say?","volume":"11","author":"Wang","year":"2015","journal-title":"Future Virol"},{"key":"10.1124\/mol.116.105346_bib58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bip.22623","article-title":"Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses","volume":"104","author":"Wang","year":"2015","journal-title":"Biopolymers"},{"key":"10.1124\/mol.116.105346_bib59","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1021\/jm301538e","article-title":"Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus","volume":"56","author":"Wang","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/mol.116.105346_bib60","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1073\/pnas.1216526110","article-title":"Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus","volume":"110","author":"Wang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.116.105346_bib61","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1021\/cr100264t","article-title":"The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives","volume":"113","author":"Wanka","year":"2013","journal-title":"Chem Rev"},{"key":"10.1124\/mol.116.105346_bib62","doi-asserted-by":"crossref","first-page":"9885","DOI":"10.1021\/ja4041412","article-title":"Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR","volume":"135","author":"Williams","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1124\/mol.116.105346_bib63","doi-asserted-by":"crossref","first-page":"17987","DOI":"10.1021\/ja508461m","article-title":"Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel","volume":"136","author":"Wu","year":"2014","journal-title":"J Am Chem Soc"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24005479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24005479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.116.105346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:17:11Z","timestamp":1739960231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24005479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0026895X24005479"],"URL":"https:\/\/doi.org\/10.1124\/mol.116.105346","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.116.105346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}